Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020

Miguel Ángel Fernández Freire; Gabriela Isabel Gálvez Salazar; Mariana Meira Scudeler; Fernanda Rodrigues-Soares; Gabriela Fernanda Jaramillo Koupermann; Andrea Paola Moreno Ocampo

doi:10.1515/dmpt-2022-0112

Article

Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020

Miguel Ángel Fernández Freire , Gabriela Isabel Gálvez Salazar , Mariana Meira Scudeler , Fernanda Rodrigues-Soares , Gabriela Fernanda Jaramillo Koupermann and Andrea Paola Moreno Ocampo

Published/Copyright: December 26, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 38 Issue 2

Abstract

Objectives

Determine the frequency of actionable mutations in non-small cell lung cancer (NSCLC) and their correlation with overall survival (OS) and the site of metastases.

Methods

We performed a descriptive cross-sectional study at the Hospital de Especialidades Eugenio Espejo, Ecuador, between 2017 and 2020. Demographic, pathological, and molecular alterations in epidermal growth factor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), Programmed death-ligand 1 (PD-L1) expression, and clinical data detailed in patients’ medical records with metastatic NSCLC were collected and analyzed.

Seventy-nine stage IV patients had NSCLC; adenocarcinoma histology represents 56 (70.9%). The predominant mutation was in EGFR (22.8%); the most common variant was the deletion of exon 19 (72.2%). The most common metastatic site was in the contralateral lung (22.3%); however, this variable showed no significant correlation to the molecular markers (p=0.057). The overall survival (OS) and the status of molecular markers are not statistically significant (p=0.27). OS was better for non-mutated EGFR than for mutated EGFR (p=0.012). However, the frequency values are unrelated to contralateral lung metastasis or survival.

Conclusions

Our frequency mutations are concordant with those found in other studies in Latin America. EGFR was the most common biomarker mutation, and there was a better OS in EGFR non-mutated patient.

Keywords: epidermal growth factor (EGFR) frequency; genetic markers; lung neoplasms

Corresponding author: Miguel Ángel Fernández Freire, Departamento de Oncología Clínica, Instituto de Posgrado de Oncología Clínica, Universidad Central del Ecuador (UCE), Pasaje C N 66-44 y Av. Eucaliptos, Quito, Ecuador, E-mail: miguelfernandez19928@gmail.com

Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The Institutional Review Board approval was obtained through the investigation department at the Hospital de Especialidades Eugenio Espejo Quito – Ecuador.

References

1. Globocan. Lung Source: Globocan 2020. International Agency for Research on Cancer (IARC); 2020, 419:7–8 pp. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf [Accessed 2021 Oct 23]. In press.Search in Google Scholar

2. Globocan. Ecuador Source: Globocan 2020. International Agency for Reserch on Cancer; 2020, 563:1–2 pp. https://gco.iarc.fr/today/data/factsheets/populations/218-ecuador-fact-sheets.pdf. In press.Search in Google Scholar

3. Travis, WD, Brambilla, E, Nicholson, AG, Yatabe, Y, Austin, JHM, Beasley, MB, et al.. The 2015 World health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243–60. https://doi.org/10.1097/jto.0000000000000630.Search in Google Scholar

4. Hirsch, FR, Scagliotti, GV, Mulshine, JL, Kwon, R, Curran, WJ, Wu, YL, et al.. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299–311. https://doi.org/10.1016/s0140-6736(16)30958-8.Search in Google Scholar PubMed

5. NCCN. Non-Small Cell Lung Cancer V.4.2020 – Follow-up – May 11, 2020. Avaliable from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiTooz-8p__AhWIUXcKHRj9A3sQFnoECB8QAQ&url=https%3A%2F%2Fwww.nccn.org%2Fguidelines%2Fguidelines-process%2Ftransparency-process-and-recommendations%2FGetFileFromFileManagerGuid%3FFileManagerGuidId%3D241ff566-37b1-4d8b-9c4b-cc8230b883e4&usg=AOvVaw0_LzIlV7x6tVbnCoSvYCRy. [Accessed 11 May 2020].Search in Google Scholar

6. Marino, FZ, Bianco, R, Marina Accardo, M, Ronchi, A, Cozzolino, I, Morgillo, F, et al.. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci 16;2019;:981–9. https://doi.org/10.1200/edbk_237863.Search in Google Scholar

7. Wadowska, K, Bil-Lula, I, Trembecki, Ł, Śliwińska-Mossoń, M. Genetic markers in lung cancer diagnosis: a review. Int J Mol Sci 2020;21:4569.10.3390/ijms21134569Search in Google Scholar PubMed PubMed Central

8. Roche cobas. cobas ® EGFR mutation test v2 for in vitro diagnostic use. Mannheim, Germany: Roche Molecular Systems; 2016:1–71 pp.Search in Google Scholar

9. Roche Ventana. VENTANA anti-ALK (D5F3) rabbit monoclonal primary Antibody. Mannheim, Germany: Roche Molecular Systems; 2015:1–4 pp.Search in Google Scholar

10. Roche Ventana. VENTANA ROS-1 (SP384) rabbit monoclonal primary antibody. Mannheim, Germany: Roche Molecular Systems; 2019, 790–6087:1–4 pp.Search in Google Scholar

11. Roche Ventana. VENTANA PD-L1 (SP263) assay. Mannheim, Germany: Ventana Medical Systems; 2018, 1.Search in Google Scholar

12. De Oliveira, ACDSM, Da Silva, AVA, Alves, M, Cronemberger, E, Carneiro, BA, Melo, JC, et al.. Molecular profile of non-small cell lung cancer in northeastern Brazil. J Bras Pneumol 2019;45:1–7. https://doi.org/10.1590/1806-3713/e20180181.Search in Google Scholar PubMed PubMed Central

13. Arrieta, O, Cardona, AF, Federico Bramuglia, G, Gallo, A, Campos-Parra, AD, Serrano, S, et al.. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011;6:1955–9. https://doi.org/10.1097/jto.0b013e31822f655f.Search in Google Scholar PubMed

14. Arrieta, O, Cardona, AF, Martín, C, Más-López, L, Corrales-Rodríguez, L, Bramuglia, G, et al.. Updated frequency of EGFR and KRAS mutations in NonSmall-cell lung cancer in Latin America: the Latin-American consortium for the investigation of lung cancer (CLICaP). J Thorac Oncol 2015;10:838–43. https://doi.org/10.1097/jto.0000000000000481.Search in Google Scholar

15. Rivas, C, Luis Martinez, EET. Prevalence of epidermal growth factor receptor (EGFR) mutation in an Ecuadorian population with non-small cell lung cancer (NSCLC). J Clin Oncol 2014;15:e19157–e19157. https://doi.org/10.1200/jco.2014.32.15_suppl.e19157.Search in Google Scholar

16. Aguiar, F, Fernandes, G, Queiroga, H, Machado, JC, Cirnes, L, Souto Moura, C, et al.. Overall survival analysis and characterization of an EGFR mutated non-small cell lung cancer (NSCLC) population. Arch Bronconeumol 2018;54:10–7. https://doi.org/10.1016/j.arbres.2017.07.012.Search in Google Scholar PubMed

17. Beypinar, I, Demir, H, Araz, M, Uysal, M. The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma. J oncol sci 2019;5:65–9. https://doi.org/10.1016/j.jons.2019.08.002.Search in Google Scholar

Received: 2022-02-27

Accepted: 2022-10-24

Published Online: 2022-12-26

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2022-0112

Keywords for this article

epidermal growth factor (EGFR) frequency; genetic markers; lung neoplasms